{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "go:GO:0006915",
      "entity_text" : "apoptosis",
      "entity_type" : "bioprocess"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ05193",
      "entity_text" : "pan-caspase inhibitor",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "In phase II clinical trials on 38 patients, emricasan, a pan-caspase inhibitor, lowered serum aminotransferase activity, liver injury and fibrosis by inhibiting hepatocytes apoptosis.",
  "reading_complete" : "2020-08-03T19:58:44Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T19:52:43Z",
  "trigger" : "lowered",
  "evidence" : [ "pan-caspase inhibitor, lowered serum aminotransferase activity, liver injury and fibrosis by inhibiting hepatocytes apoptosis" ],
  "pmc_id" : "6185929",
  "score" : 0
}